These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 33105763)

  • 1. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
    Hou YC; Zheng CM; Yen TH; Lu KC
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.
    Kalra S; Singh V; Nagrale D
    Adv Ther; 2016 Sep; 33(9):1502-18. PubMed ID: 27423646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.
    Gronda E; Lopaschuk GD; Arduini A; Santoro A; Benincasa G; Palazzuoli A; Gabrielli D; Napoli C
    Can J Physiol Pharmacol; 2022 Feb; 100(2):93-106. PubMed ID: 35112597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
    Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure.
    Choday S; Ravi N; Parisapogu A; Ojinna BT; Sherpa ML
    Cureus; 2023 Feb; 15(2):e34687. PubMed ID: 36909046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
    Koh ES; Kim GH; Chung S
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):359-372. PubMed ID: 37482684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SGLT2 inhibitors in diabetic and non-diabetic nephropathies].
    Scheen M; Zanchi A; Martin PY; De Seigneux S
    Rev Med Suisse; 2021 Feb; 17(727):378-382. PubMed ID: 33625802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review.
    Yaribeygi H; Sathyapalan T; Maleki M; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Jan; 240():117090. PubMed ID: 31765648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.
    Chiriacò M; Tricò D; Solini A
    Curr Opin Pharmacol; 2022 Oct; 66():102272. PubMed ID: 35964531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.